Back
Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Journal article

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.

  • 2015-04-07
Published in:
  • Expert review of clinical immunology. - 2015
anakinra
biological agents
canakinumab
macrophage activation syndrome
risk factors
systemic juvenile idiopathic arthritis
tocilizumab
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Arthritis, Juvenile
Humans
Immunity, Innate
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Interleukin-6
Macrophage Activation
Risk Factors
Translational Medical Research
English Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory condition characterized by fever, lymphadenopathy, arthritis, rash and serositis. Systemic inflammation has been associated with dysregulation of the innate immune system, suggesting that SJIA is an autoinflammatory disorder. IL-1 and IL-6 play a major role in the pathogenesis of SJIA, and treatment with IL-1 and IL-6 inhibitors has shown to be highly effective. However, complications of SJIA, including macrophage activation syndrome, limitations in functional outcome by arthritis and long-term damage from chronic inflammation, continue to be a major issue in SJIA patients' care. Translational research leading to a profound understanding of the cytokine crosstalk in SJIA and the identification of risk factors for SJIA complications will help to improve long-term outcome.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/53545
Statistics
Document views: 27 File downloads: